About eledon pharmaceuticals inc - ELDN
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
ELDN At a Glance
Eledon Pharmaceuticals, Inc.
19800 MacArthur Boulevard
Irvine, California 92612
| Phone | 1-949-238-8090 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -45,617,000.00 | |
| Sector | Health Technology | Employees | 33 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ELDN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.405 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.559 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.014 |
ELDN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,382,333.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ELDN Liquidity
| Current Ratio | 7.397 |
| Quick Ratio | 7.397 |
| Cash Ratio | 7.269 |
ELDN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -19.534 |
| Return on Equity | -35.789 |
| Return on Total Capital | -33.195 |
| Return on Invested Capital | -35.66 |
ELDN Capital Structure
| Total Debt to Total Equity | 0.469 |
| Total Debt to Total Capital | 0.466 |
| Total Debt to Total Assets | 0.27 |
| Long-Term Debt to Equity | 0.349 |
| Long-Term Debt to Total Capital | 0.206 |